Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 5, 2013

Primary Completion Date

October 2, 2024

Study Completion Date

October 2, 2024

Conditions
Non-small Cell Lung Cancer
Interventions
RADIATION

Stereotactic Body Radiation Therapy (SBRT)

DRUG

cisplatin or carboplatin-based

Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, East White Plains

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

07920

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01899989 - Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter